Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users

Diabetes, Obesity & Metabolism
Anthony P NunesDavid D Dore

Abstract

Certain treatments for type 2 diabetes mellitus cause hypoglycaemia and weight gain, and thus might counteract the benefits of intensive glucose control. We quantify the association of cardiovascular disease (CVD) outcomes with hypoglycaemia and weight gain among patients with type 2 diabetes treated with sulfonylureas. This cohort study included patients from January 2009 through December 2014 who were selected from within a deidentified nationwide electronic health records repository, including multiple provider networks and electronic medical records systems. Hypoglycaemia measures from structured data fields and free text clinical notes were categorized as serious or non-serious. Covariate adjusted Poisson regression analysis was used to assess the association between frequency of hypoglycaemia (by severity), or magnitude of weight change, and incidence of acute myocardial infarction (AMI), congestive heart failure (CHF) and stroke. Among 143 635 eligible patients, we observed 5669 cases of AMI, 14 109 incident cases of CHF and 7017 cases of stroke. Overall incidence rates were 1.53, 4.26 and 1.92 per 100 person-years for AMI, CHF and stroke, respectively. The associations between overall hypoglycaemia and each of the CVD o...Continue Reading

References

Mar 5, 2003·Annals of Internal Medicine·Edward W GreggDavid F Williamson
May 27, 2003·Diabetes Care·Philip E CryerHarry Shamoon
Nov 25, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·J N HendersonB M Frier
Sep 24, 2004·Annals of Internal Medicine·Elizabeth SelvinSherita Hill Golden
Jan 27, 2005·Drugs·Andrew J Krentz, Clifford J Bailey
Apr 28, 2005·Diabetes Care·UNKNOWN Workgroup on Hypoglycemia, American Diabetes Association
May 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·L A DonnellyUNKNOWN DARTS/MEMO Collaboration
Oct 4, 2005·Current Medical Research and Opinion·Ruth E DavisCraig J Currie
Apr 3, 2008·BMC Endocrine Disorders·Adit A GindeCarlos A Camargo
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
May 29, 2010·Diabetes Care·Cyrus V DesouzaVivian Fonseca
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Jun 8, 2012·Diabetes Technology & Therapeutics·Janet K Snell-Bergeon, R Paul Wadwa
Jun 16, 2012·Journal of Diabetes and Its Complications·Setareh A WilliamsVivian Fonseca
Jan 1, 2012·Journal of Diabetes and Metabolic Disorders·Gita ShafieeBagher Larijani
Aug 1, 2013·BMJ : British Medical Journal·Atsushi GotoMitsuhiko Noda
Feb 25, 2014·Current Diabetes Reports·Peter M Thulé, Guillermo Umpierrez
Apr 17, 2016·Journal of Diabetes and Its Complications·Katharina Mattishent, Yoon Kong Loke

❮ Previous
Next ❯

Citations

Jun 20, 2018·Annals of the New York Academy of Sciences·Logan SmithKunjan R Dave
Dec 18, 2018·Frontiers in Cardiovascular Medicine·Devinder S DhindsaMichael D Shapiro
Dec 11, 2020·Journal of Diabetes·Zachary Bloomgarden, Robert Chilton
Mar 17, 2021·American Heart Journal·Angela LowensternJ Matthew Brennan
Jul 31, 2021·American Journal of Preventive Cardiology·Harold E BaysPeter P Toth
Aug 14, 2021·Journal of the American Heart Association·J Matthew BrennanEric D Peterson
Sep 12, 2020·Current Pharmaceutical Design·Niki KatsikiDimitri P Mikhailidis

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Rune ErichsenJohn A Baron
© 2022 Meta ULC. All rights reserved